NEW CAMKII THERAPEUTIC TARGETS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
Grant number: 1125453 | Funding period: 2017 - 2021
Deaths associated with impaired heart muscle relaxation and unstable cardiac cycle rhythm are increasing. The mechanisms by which these pathologies occur are not understood and clinical therapies are lacking. We have novel evidence to suggest that a key signalling protein, CaMKII, is critically involved in the development of these forms of heart pathology. This goal of this project is to identify how CaMKII is implicated in heart failure and dysrhythmia as a basis for designing new therapies.
Related publications (1)
Cardiomyocyte functional screening: interrogating comparative electrophysiology of high-throughput model cell systems
Simon P Wells, Helen M Waddell, Choon Boon Sim, Shiang Y Lim, Gabriel B Bernasochi, Davor Pavlovic, Paulus Kirchhof, Enzo R Porrello, Lea MD Delbridge, James R Bell
Cardiac arrhythmias of both atrial and ventricular origin are an important feature of cardiovascular disease. Novel antiarrhythmic..